Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A universal polysaccharide conjugated vaccine against O111 E. coli

Full text
Author(s):
Show less -
Andrade, Gabrielle R. [1] ; New, Roger R. C. [2] ; Sant'Anna, Osvaldo A. [3] ; Williams, Neil A. [4] ; Alves, Rosely C. B. [5] ; Pimenta, Daniel C. [6] ; Vigerelli, Hugo [6] ; Melo, Bruna S. [1] ; Rocha, Leticia B. [1] ; Piazza, Roxane M. F. [1] ; Mendonca-Previato, Lucia [7] ; Domingos, Marta O. [1]
Total Authors: 12
Affiliation:
[1] Inst Butantan, Lab Bacteriol, Sao Paulo - Brazil
[2] Proxima Concepts Ltd, London - England
[3] Inst Butantan, Lab Immunochem, Sao Paulo - Brazil
[4] Univ Bristol, Dept Cellular & Mol Med, Bristol, Avon - England
[5] Inst Butantan, Lab Virol, Sao Paulo - Brazil
[6] Inst Butantan, Lab Biochem, Sao Paulo - Brazil
[7] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas, Rio de Janeiro - Brazil
Total Affiliations: 7
Document type: Journal article
Source: HUMAN VACCINES & IMMUNOTHERAPEUTICS; v. 10, n. 10, p. 2864-2874, OCT 2014.
Web of Science Citations: 4
Abstract

E. coli O111 strains are responsible for outbreaks of blood diarrhea and hemolytic uremic syndrome throughout the world. Because of their phenotypic variability, the development of a vaccine against these strains which targets an antigen that is common to all of them is quite a challenge. Previous results have indicated, however, that O111 LPS is such a candidate, but its toxicity makes LPS forbidden for human use. To overcome this problem, O111 polysaccharides were conjugated either to cytochrome C or to EtxB (a recombinant B subunit of LT) as carrier proteins. The O111-cytochrome C conjugate was incorporated in silica SBA-15 nanoparticles and administered subcutaneously in rabbits, while the O111-EtxB conjugate was incorporated in Vaxcine(TM), an oil-based delivery system, and administered orally in mice. The results showed that one year post-vaccination, the conjugate incorporated in silica SBA-15 generated antibodies in rabbits able to inhibit the adhesion of all categories of O111 E. coli to epithelial cells. Importantly, mice immunized orally with the O111-EtxB conjugate in Vaxcine(TM) generated systemic and mucosal humoral responses against all categories of O111 E. coli as well as antibodies able to inhibit the toxic effect of LT in vitro. In summary, the results obtained by using 2 different approaches indicate that a vaccine that targets the O111 antigen has the potential to prevent diarrhea induced by O111 E. coli strains regardless their mechanism of virulence. They also suggest that a conjugated vaccine that uses EtxB as a carrier protein has potential to combat diarrhea induced by ETEC. (AU)

FAPESP's process: 13/07467-1 - CeTICS - Center of Toxins, Immune-Response and Cell Signaling
Grantee:Hugo Aguirre Armelin
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 12/11325-5 - Evaluation of the immune response induced by an oral vaccine against O26 and O111 E. coli
Grantee:Marta de Oliveira Domingos
Support Opportunities: Regular Research Grants